The differences of clinicopathological, laboratory features, and disease activity between dipeptidyl peptidase 4 inhibitors-induced bullous pemphigoid and classic bullous pemphigoid
- Conditions
- dipeptidyl peptidase 4 inhibitors-induced bullous pemphigoiddrug-induced bullous pemphigoid,diabetes mellitus type 2
- Registration Number
- TCTR20190605003
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 101
Patients aged 15 years or older who were diagnosed with DM2 before the onset of BP were recruited. The diagnosis of BP was confirmed in the patients possessing at least 3 out of the 4 following criteria: clinical consistency with BP; subepidermal separation with dermal inflammatory-cell infiltrations in skin histopathology; IgG and/or C3 depositions in linear pattern along the DEJ by direct immunofluorescence (DIF) or linear IgG on the epidermal side of the skin in salt-split indirect immunofluorescence (IIF); the positive results of anti-BP180 IgG and/or anti-BP230 enzyme-linked immunosorbent assays (ELISA) in patient with equivocal DIF and IIF.
The patients whose diagnoses were not consistent with BP were dismissed. Sixteen patients having BP induced by other drugs apart from DPP4i agents or having incomplete records were excluded. Five patients were excluded due to conflicting relations and the remaining 16 patients were categorized as DPP4i-induced BP cases.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method disease activity 6 months Bullous Pemphigoid Disease Area Index (BPDAI)
- Secondary Outcome Measures
Name Time Method clinical features 6 months Clinical features included BP patterns (localized or generalized), atypical forms of BP (serpiginous,Histopathological features 6 months eosinophilic spongiosis, presence of necrotic keratinocytes, inflammatory-cell infiltrations,laboratory results 6 months complete blood count (CBC) such as level of hemoglobin, platelets and absolute eosinophil count,Immunofluorescence (DIF/IIF) features 6 months The autoantibodies for BP180 and BP230 were measured using a commercial ELISA method.